Journal article
Novel use of Carboplatin, Etoposide and Durvalumab as Neoadjuvant Therapy in Treatment of Small Cell Bladder Cancer
Urology case reports, Vol.62, 103165
09/2025
DOI: 10.1016/j.eucr.2025.103165
PMCID: PMC12395055
PMID: 40894098
Abstract
Small cell carcinoma of the bladder (SCCB) is a rare and aggressive variant of bladder cancer requiring multimodal treatment. We present a case of an 82-year-old male with SCCB with bulky pelvic adenopathy treated with a novel neoadjuvant combination of carboplatin, etoposide, and durvalumab with complete response of the small cell component. We also describe a rare complication of retinopathy resulting from this treatment. This study presents the potential efficacy and promise of adding immunotherapy to neoadjuvant chemotherapy for SCCB to achieve a long-term cure.
•Checkpoint inhibitors as neoadjuvant therapy for small cell bladder cancer (SCCB)•Complete pathologic response in SCCB to durvalumab, cisplatin, and etoposide•Complication of retinopathy from neoadjuvant carboplatin, etoposide, durvalumab
Details
- Title: Subtitle
- Novel use of Carboplatin, Etoposide and Durvalumab as Neoadjuvant Therapy in Treatment of Small Cell Bladder Cancer
- Creators
- Victoria E. Gonzalez - Department of Urology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr. Iowa City, IA, 52242 USAEdward Linton - University of Iowa, Ophthalmology and Visual SciencesTimothy Boyce - University of IowaLaila Dahmoush - University of IowaHelen Y. Hougen - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Urology case reports, Vol.62, 103165
- DOI
- 10.1016/j.eucr.2025.103165
- PMID
- 40894098
- PMCID
- PMC12395055
- NLM abbreviation
- Urol Case Rep
- ISSN
- 2214-4420
- eISSN
- 2214-4420
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 09/2025
- Academic Unit
- Pathology; Urology; Ophthalmology and Visual Sciences
- Record Identifier
- 9984948008502771
Metrics
2 Record Views